CL
BBIO icon

CSS LLC’s BridgeBio Pharma BBIO Stock Holding History

CSS LLC’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,100
Closed -$314K – 997
2025
Q4 		$314K Buy
+4,100
New +$269K 0.01% 674
2023
Q2 		– Sell
-42,000
Closed -$696K – 900
2023
Q1 		$696K Buy
+42,000
New +$490K 0.05% 259

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's BBIO Position: Q3 2024 in Review

CSS LLC sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 6,481 shares — an estimated $164K sold.

CSS LLC first reported a position in BBIO in Q2 2024 and held it in 1 quarter. The position peaked at $164K in Q2 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • CSS LLC reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • CSS LLC sold 6,481 BridgeBio Pharma shares in Q3 2024, an estimated $164K.
  • CSS LLC first reported a position in BridgeBio Pharma in Q2 2024 and held it in 1 quarter.
  • CSS LLC's BridgeBio Pharma position peaked at $164K in Q2 2024.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on CSS LLC's 13F filing for Q3 2024, filed 14 Nov 2024.